Detection of Chromosomal Aberrations in Non-small Cell Lung Cancer (NSCLC) Using Fluorescent in Situ Hybridization (FISH) (ALK Test)



Status:Recruiting
Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:20 - 90
Updated:2/7/2015
Start Date:May 2012
Contact:Sheila Dobin,, Ph.D.
Email:SDOBIN@swmail.sw.org
Phone:254-215-9031

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Concordance Study for Detection of Chromosomal Aberrations Using FISH (ALK Test)in Non-small Cell Lung Cancer (NSCLC)

The purpose of the study is the identification of chromosomal aberrations in non-small cell
lung cancer (NSCLC) .

The imaging system is intended for diagnostic use as an aid to the pathologist in the
detection, counting and classifying ALK FISH stained lung samples.

The ALK Break Apart FISH test detects chromosomal aberrations via fluorescence in situ
hybridization (FISH) in formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer
(NSCLC) tissue specimens. The FDA approved ALK kit is designed to detect rearrangements
involving the ALK gene (2p23). Results from the ALK Kit are intended for use, in conjunction
with and not in lieu of current standard diagnostic procedures, as an aid for the
pathologist in the identification of patients eligible for treatment with XALKORI®
(crizotinib).

Inclusion Criteria:

- Well stained slides with bright FISH signals

Exclusion Criteria:

- Very old slides that were already bleached
We found this trial at
1
site
Scott & White Hospital
Temple, Texas 76508
?
mi
from
Temple, TX
Click here to add this to my saved trials